Phase 3 results posted: A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years — Janssen Research & Development, LLC
Why now
Thesis: Large E. coli vaccine trial results posted
Catalyst to watch: Regulatory submission decision
Main risk: Vaccine efficacy may disappoint
Why it matters
A large vaccine trial's results inform Janssen's prevention pipeline for invasive E. coli disease.
Details
Sponsor: Janssen Research & Development, LLC; Status: Completed; Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention; Interventions: ExPEC9V, Placebo; Enrollment: 17797 (actual); First posted: 2021-05-24; Results posted: 2026-09-28; NCT: NCT04899336
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-28 12:00 UTC